Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17237651 | 0.87 | POLB (0.32) | LMNASMN1; SMN2TSHR | |
| SCHEMBL1948850 | 0.86 | LMNA (0.32) | LMNASMN1; SMN2 | |
| SCHEMBL1948852 | 0.85 | LMNA (0.31) | LMNASMN1; SMN2 | |
| SCHEMBL6521242 | 0.82 | CYP3A4 (0.36) | LMNASMN1; SMN2 | |
| SCHEMBL6527257 | 0.80 | SLC6A4 (0.33) | TSHR | |
| SCHEMBL6523153 | 0.76 | SMN1; SMN2 (0.36) | LMNASMN1; SMN2 | |
| SCHEMBL1948426 | 0.75 | TSHR (0.30) | TSHR | |
| SCHEMBL6527272 | 0.74 | KMT2A (0.37) | LMNASMN1; SMN2 | |
| SCHEMBL1948424 | 0.73 | ADRB2 (0.32) | TSHR | |
| SCHEMBL6519022 | 0.73 | ALDH1A1 (0.36) | LMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8987242-B2 | Morpholinone compounds as factor IXA inhibitors | MERCK SHARP & DOHME CORP. (US) | 2015-03-24 | — | — | US | disclosed |
| US-8642582-B2 | Morpholinone compounds as factor IXa inhibitors | MERCK SHARP & DOHME CORP. (US) | 2014-02-04 | — | — | US | disclosed |
| US-20110059958-A1 | MORPHOLINONE COMPOUNDS AS FACTOR IXA INHIBITORS | MERCK SHARP & DOHME LLC | 2011-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110059958-A1 | MORPHOLINONE COMPOUNDS AS FACTOR IXA INHIBITORS | SERPINC1, F9, F8 | LMNA 95/4885SMN1; SMN2 1538/4885TSHR 2827/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.